In addition, Abattis
will make milestone-based payments to such shareholders of Gabriola of CDN 5m upon Gabriola's receipt of a cultivation license under the ACMPR and CDN 5m upon Gabriola's receipt of a sales license under the ACMPR.
Moving forward within Abattis
, Green Tree will continue to be engaged in expanding its product offerings for alternate cannabis products, including capsules, and lotions.
Don Ki Kim, CEO of GD Pharma, commented: "Global Damon Pharma is very happy to make our partnership with Abattis
is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada.
We feel that testing services provided by Abattis
will give us the peace of mind that consumers require regarding dosage quality and safety said Jeff Guignard, Executive Director of ABLE BC.
This process is expected to increase the delivery of phytocannabinoids in Abattis
Cannabidiol-rich hemp oil from 50% to 90%.
is also pleased to announce that it is undertaking another non-brokered private placement (the New Private Placement) for gross proceeds to the Company of up to $8 million.
Mike Withrow, chief executive officer of Abattis
, said that this is the first in three steps toward becoming a fully reporting issuer with the SEC.
The Company also announces that, pursuant to the distributorship agreement between Abattis
and Suzhou Raybot Material Tech Corp.
moves forward with its business plans, DTC eligibility will extend its reach to a broader audience of investors, setting the stage for exposure on an international scale.
On April 20, 2017, Abattis
signed an exclusive distribution agreement with Suzhou Raybot Material Tech Corp.
Abenante is the President and CEO of Abattis
and its subsidiaries.